Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.
Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. Rosenbaum E, et al. Among authors: jones rl. Eur J Cancer. 2022 Nov;176:155-163. doi: 10.1016/j.ejca.2022.09.003. Epub 2022 Oct 8. Eur J Cancer. 2022. PMID: 36215947 Free PMC article. Clinical Trial.
Chemotherapy in clear cell sarcoma.
Jones RL, Constantinidou A, Thway K, Ashley S, Scurr M, Al-Muderis O, Fisher C, Antonescu CR, D'Adamo DR, Keohan ML, Maki RG, Judson IR. Jones RL, et al. Med Oncol. 2011 Sep;28(3):859-63. doi: 10.1007/s12032-010-9502-7. Med Oncol. 2011. PMID: 20390470
Immune-based therapies for sarcoma.
Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL. Pollack SM, et al. Among authors: jones rl. Sarcoma. 2011;2011:438940. doi: 10.1155/2011/438940. Epub 2011 Jan 23. Sarcoma. 2011. PMID: 21331153 Free PMC article.
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.
Schöffski P, Taron M, Jimeno J, Grosso F, Sanfilipio R, Casali PG, Le Cesne A, Jones RL, Blay JY, Poveda A, Maki RG, Nieto A, Tercero JC, Rosell R. Schöffski P, et al. Among authors: jones rl. Eur J Cancer. 2011 May;47(7):1006-12. doi: 10.1016/j.ejca.2011.01.016. Epub 2011 Mar 4. Eur J Cancer. 2011. PMID: 21376569
Systemic therapy in primary angiosarcoma of the spleen.
Ferreira BP, Rodler ET, Loggers ET, Pollack SM, Jones RL. Ferreira BP, et al. Among authors: jones rl. Rare Tumors. 2012 Oct 10;4(4):e55. doi: 10.4081/rt.2012.e55. Epub 2012 Nov 13. Rare Tumors. 2012. PMID: 23372919 Free PMC article.
The evolution of systemic therapy in sarcoma.
Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL. Constantinidou A, et al. Among authors: jones rl. Expert Rev Anticancer Ther. 2013 Feb;13(2):211-23. doi: 10.1586/era.12.161. Expert Rev Anticancer Ther. 2013. PMID: 23406562 Review.
Clinical benefit of trabectedin in uterine adenosarcoma.
Schroeder BA, Rodler ET, Loggers ET, Pollack SM, Jones RL. Schroeder BA, et al. Among authors: jones rl. Med Oncol. 2013 Jun;30(2):501. doi: 10.1007/s12032-013-0501-3. Epub 2013 Feb 28. Med Oncol. 2013. PMID: 23456619
Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.
Meyer JM, Perlewitz KS, Hayden JB, Doung YC, Hung AY, Vetto JT, Pommier RF, Mansoor A, Beckett BR, Tudorica A, Mori M, Holtorf ML, Afzal A, Woodward WJ, Rodler ET, Jones RL, Huang W, Ryan CW. Meyer JM, et al. Among authors: jones rl. Clin Cancer Res. 2013 Dec 15;19(24):6902-11. doi: 10.1158/1078-0432.CCR-13-1594. Epub 2013 Oct 16. Clin Cancer Res. 2013. PMID: 24132922 Free PMC article. Clinical Trial.
1,354 results